

Docket No: AM100012OX1

Patent

In re of Application of: MARK, R.T. et al.
Serial No.: 09/425,501 Group Art No.: 1637
Filed: October 22, 1999 Examiner: Suryaprabha Chunduru
For: PABLO, A POLYPEPTIDE THAT INTERACTS WITH BCL-XL
AND USES RELATED THERETO
Confirmation No.: 9642
Customer Number: 25291

RECEIVED

NOV 08 2002

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicant submits herewith patents, publications, or other information of which he is aware in accordance with 37 CFR 1.56. This Supplemental Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL 95385302 US addressed to the Commissioner for Patents, Washington, DC 20231.

11/14/02

Date


Elizabeth Ruzich

11/13/2002 TJOHNS04 00000001 071060 09425501

01 FC:1806 180.00 CH

2. Identification of Time of Filing

This Information Disclosure Statement

- a. is filed within three months of the filing date of the application.
- b. is filed before the mailing date of a first Office Action on the merits.
- c. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. Certification under 37 CFR 1.97(e) and 1.704(d)

The undersigned attorney certifies

- a. that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.

Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Serial Number , filed on for .

Concise Explanation

Documents cited above which are not in the English Language

- a. have been explained in the specification.
- b. have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

Fees

Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00


Method of Payment of Fees:

Charge Deposit Account No. 07-1060 in the amount of \$180.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.



Gavin T. Bogle

Limited Recognition Under 37 C.F.R. 10.9(b)

Wyeth
Patent Law Department
Five Giralta Farms
Madison, NJ 07940
Tel. No. (617) 665-8079